Pictura Bio

Executive Summary

Pictura Bio, founded in 2021 and headquartered in London, UK, is an early-stage med-tech company developing a novel rapid diagnostics platform for infectious diseases. The platform integrates proprietary hardware with machine learning-based computer vision to detect and differentiate multiple pathogens from a single sample at the point of care within one minute. By aiming to deliver laboratory-quality results in a fraction of the time and cost, Pictura Bio addresses critical needs in settings where timely diagnosis is essential, such as emergency departments, primary care, and resource-limited environments. The company's mission is to democratize access to advanced diagnostics, reducing reliance on centralized labs and enabling faster clinical decision-making. As a private, pre-revenue entity with no disclosed funding rounds or regulatory milestones, Pictura Bio operates in a competitive landscape but differentiates itself through its speed and breadth of pathogen detection. Its early-stage status implies significant execution risk, yet the concept has the potential to disrupt point-of-care testing if successfully developed and validated.

Upcoming Catalysts (preview)

• Q4 2026Series A Funding Announcement50% success
• Q1 2027First Regulatory Submission (CE Mark or FDA 510(k))30% success
• Q2 2027Clinical Validation Study Results40% success